Formulation and evaluation of Lornoxicam loaded Lyotropic liquid crystalline gel
GIT irritation is prominent limitation with the use of Non-steroidal anti-inflammatory drugs (NSAID’s). There is rising interest in designing formulations which will deliver the drug at the site of action as topical gels, to avoid GIT irritation and other systemic side effects. Liquid Crystal phase has emerged as a novel material for the preparation of topical drug delivery system. In present study the attempt is made to prepare Lornoxicam loaded lyotropic liquid crystalline gel using glycerol monooleate. Glycerol monooleate is biocompatible, bioadhesive, penetration enhancer and sustain release agent. It also promotes ceramide extraction and enhancement of lipid fluidity in the stratum corneum region of the skin. Five formulation of lornoxicam were prepared and evaluated for parameters like drug content, viscosity, spreadability, Extrudability In-vitro drug release along with in vivo study. In-Vitro and Ex-Vivo drug release kinetics showed that there was 72.85% and 77.98% drug release within 48 hrs. Skin irritation test suggested that prepared formulation was safe for human use. In-Vivo evaluation of this formulation was done by carrageenan induced rat paw edema anti-inflammatory model.
Keywords: Lornoxicam, GMO, Lyotropic liquid crystal, Anti-Inflammatory, Topical drug delivery
2) AMMAR, H, GHORAB, A, MAHMOUD A, MAKRAM S, T, NOAHI, S 2012 Topical liquid crystalline gel containing lornoxicam/cyclodextrin complex, J, Inc Phinom. Macro. Chem; 73, 161-175.
3) AYTEKIN, M, NESLIHAN, R, IDE, S, ELIF, S, SUEDA, H, 2012. Formulation and characterization of liquid crystal systems containing azelaic acid for topical delivery, Drug Develop. Ind. Pharm; 1-12.
4) BANKER, G.B.S. RODE, C.T., 1979. “Modern Pharmacist”, 40, Marcel Dekker, New york, app, 263-311.
5) CHRISTEL, C, MUELLER-GOYMANN, 2007. Encyclopedia of Pharmaceutical Technology: Drug Delivery: Liquid crystal in, James swarbrick third edition, 2, pp, 1114-1131.
6) BHOWMIK, D, GOPINATH, H, KUMAR, P. B. 2012 Recent Advances in Novel Topical drug Delivery System, The Pharma. Innov; 1(9), 12-31.
7) GUY, R., HADGRAFT, J., 1989. Selection of drug candidates for transdermal drug delivery. In transdermal Drug Delivery : Developmental Issues and Research Initiatives, J. Hadgraft, R. H. Guy (eds.), Marcil Dekker Inc., New York, USA, PP. 59-81.
8) KELEB, E., SHARMA, K., MOSA, E, ALJAHWIZ ABD-ALKADAR.., 2010. Transdermal Drug delivery System-Design and Evaluation, Int. j. Pharm. Sci; 201-211.
9) WALTERS, A. K., ROBERTS, M. S. 2002. The strcture, and function of skin. In Dermatological and Transdermal formulations. K. A. Walters (ed.), Marcel dekkerInc, New York, USA, pp. 1-39.
10) Buck, P, 2004. Skin barrier function: effect or age, race and inflammatory disease. Pharmacology; 57,807-816.
11) JAIN, A., GUPTA, Y., JAIN, S., 2010. Development and characterization of Ketconazole emulgel for topical drug delivery, Der Pharmacia sinica, 1(3), 221-231
12) BENTLY, V, B, LARA, M. G, COLLETT, J. H, 2005. In vitro drug release mechanism and drug loading studies of cubic phase gels, Int, J. Pharm ; 293, 241-250.
13) LALIT KUMAR, RUCHI VERMA, 2010. In vitro evaluation of topical gel prepared using natural polymer. International Journal of Drug Delivery 2 (2010) 58-63.
14) BOYD, J. B. DAVEY, G, WHITTAKER, V. D. 2006, Hexosomes formed from glycerate surfactants Formulation as a colloidal carrier for irinotecam, Int. j. Pharm; 318, 154-162.
15) BOYD, J, B, PHAN, S, FONG, W, KIRBY, N. HANLEY, T, 2011. Evaluating the link between self-assembled mesophase structure and drug release, Int. J. Pharm; 421, 176-182.
16) CEVC, G, 2004. Lipid Vesical and other colloids as drug carriers in the skin, Adv. Drug Deliv; 56(5), 675-711.
17) DONNELLY, R, F, MORROW, D, J, MCCARRON, P. A, WOOLFSON, A. D. 2007. Innovative Strategies for Enhancing Topical and Transdermal Drug Delivery, J. Open Drug Deliv; 1, 36-59.
18) JAIN, H., GHULE, R., JOSHI , G, MAURYA, J., TRIVEDI, N., : Liquid Crystal As Accelerant In Drug Absorption From Topical formulations, Int. Res. J. Pharm; 2(4)
19) LOPES, L, PHELES, J, 2011. In situ gelling hexagonal phases for sustained release of an anti- addiction drug, Collod. Surf. B; 87, 391-398.
20) NESSE M, G, IDIT, A, DIMA, FL, ABRAHAM, A, 2009. Solubilization of food bioactive within lyotropic liquid crystalline mesophases, Curr. Opin. Cojlloed Interface Sci; 14, 21-32.
21) NISSIM, G, DORON, Y, RIVKA, E, DIMA, L, ABRAHAM, A, 2010. In vitro permeation of diclofenac salts form lyotropic liquid crystalline systems, Colloids Surf. B; 78, 185-192
22) UNITED STATE PHARMACOPEIA 30 National formulary 25, 2007. US pharmacopieal Convention, USA.
23) YAMAD, K, YAMASHITA, J., TODO, H., MIYAMOTO, K., 2011. Preparation and Evaluation of Liquid Crystal Formulations with Skin-permeation-enhancing Abilities for Entrapped Drugs, J. Oleio Sci; 60(1)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).